The FDA has approved Imuldosa, a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.
GlobalData on MSN5d
Lilly touts Omvoh’s superiority over J&J’s Stelara in Crohn’sStelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its ...
PRNewswire Ahmedabad Gujarat [India] October 19 Accord Healthcare Limited Accord announces that the Committee for Medicinal ...
Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.
The drug is approved for multiple inflammatory conditions and is expected to launch in the first half of 2025.
PRNewswire Ahmedabad Gujarat [India] October 14 Accord BioPharma Inc the US specialty division of Intas Pharmaceuticals Ltd ...
Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's ...
Number 5: The FDA has approved Imuldosa (ustekinumab-srlf), a biosimilar referencing Stelara (ustekinumab), for the treatment of autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ...
FDA approves the biologics license application (BLA) that Dong-A submitted in 2023 for Imuldosa, a biosimilar referencing ...
Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.
Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback